TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
TC BioPharm (NASDAQ: TCBP) has announced a research planning collaboration with Dr. Carlos Maluquer de Motes for developing a treatment for Monkeypox. Dr. Maluquer de Motes is a Reader and Principal Investigator at the University of Surrey, with expertise in viral diseases. TC BioPharm believes their lead therapeutic TCB008 could play a important role in treating Mpox and other infectious diseases by providing a bolstered level of gamma delta t-cells to generate a more effective immune response.
The company also plans to explore TCB008's use in a prophylactic setting for infectious diseases, potentially supporting immune-compromised patients or those at high risk of infection. Mpox, an infectious viral disease affecting humans and animals, has seen over 100,000 confirmed cases and 200 deaths globally since monitoring began in 2022, according to the World Health Organization.
TC BioPharm (NASDAQ: TCBP) ha annunciato una collaborazione per la pianificazione della ricerca con il Dr. Carlos Maluquer de Motes per sviluppare un trattamento per il vaiolo delle scimmie. Il Dr. Maluquer de Motes è un docente e ricercatore principale presso l'Università di Surrey, con esperienza nelle malattie virali. TC BioPharm ritiene che il loro principale trattamento TCB008 potrebbe svolgere un ruolo importante nel trattamento dell'Mpox e di altre malattie infettive, fornendo un livello potenziato di cellule T gamma delta per generare una risposta immunitaria più efficace.
La società prevede anche di esplorare l'uso di TCB008 in un contesto profilattico per le malattie infettive, potenzialmente a sostegno dei pazienti immunocompromessi o di quelli ad alto rischio di infezione. L'Mpox, una malattia virale infettiva che colpisce gli esseri umani e gli animali, ha registrato oltre 100.000 casi confermati e 200 decessi a livello globale dalla sua monitorizzazione iniziata nel 2022, secondo l'Organizzazione Mondiale della Sanità.
TC BioPharm (NASDAQ: TCBP) ha anunciado una colaboración para la planificación de la investigación con el Dr. Carlos Maluquer de Motes para desarrollar un tratamiento para la viruela del simio. El Dr. Maluquer de Motes es lector e investigador principal en la Universidad de Surrey, con experiencia en enfermedades virales. TC BioPharm cree que su principal terapia TCB008 podría desempeñar un papel importante en el tratamiento del Mpox y otras enfermedades infecciosas al proporcionar un nivel reforzado de células T gamma delta para generar una respuesta inmunitaria más efectiva.
La compañía también planea explorar el uso de TCB008 en un entorno profiláctico para enfermedades infecciosas, apoyando potencialmente a pacientes inmunocomprometidos o aquellos con alto riesgo de infección. Mpox, una enfermedad viral infecciosa que afecta a humanos y animales, ha visto más de 100,000 casos confirmados y 200 muertes a nivel mundial desde que comenzó su monitoreo en 2022, según la Organización Mundial de la Salud.
TC BioPharm (NASDAQ: TCBP)는 Dr. Carlos Maluquer de Motes와 함께 연구 계획 협업을 발표하여 원숭이두창 치료제 개발을 추진하고 있습니다. Maluquer de Motes 박사는 서리 대학교의 독서 교수이자 주요 연구원으로, 바이러스 질병에 대한 전문 지식이 있습니다. TC BioPharm은 그들의 주요 치료제 TCB008이 Mpox 및 기타 감염성 질병 치료에서 중요한 역할을 할 수 있다고 믿으며, 감마 델타 T 세포의 향상된 수준을 제공하여 더 효과적인 면역 반응을 생성할 수 있도록 합니다.
회사는 또한 TCB008의 감염병에 대한 예방적 사용을 탐색할 계획이며, 이는 면역 약화 환자나 감염 위험이 높은 환자를 지원할 수 있습니다. Mpox는 인간과 동물에게 영향을 미치는 전염성 바이러스 질병으로, 2022년 모니터링 시작 이후 전 세계적으로 100,000건 이상의 확진 사례와 200건의 사망이 발생했습니다. 이는 세계 보건 기구의 통계에 따른 것입니다.
TC BioPharm (NASDAQ: TCBP) a annoncé une collaboration pour la planification de la recherche avec le Dr Carlos Maluquer de Motes pour développer un traitement contre la variole des singes. Le Dr Maluquer de Motes est lecteur et chercheur principal à l'Université de Surrey, avec une expertise dans les maladies virales. TC BioPharm croit que leur traitement principal TCB008 pourrait jouer un rôle important dans le traitement de l'Mpox et d'autres maladies infectieuses en fournissant un niveau renforcé de cellules T gamma delta pour générer une réponse immunitaire plus efficace.
L'entreprise prévoit également d'explorer l'utilisation de TCB008 dans un cadre prophylactique pour les maladies infectieuses, pouvant potentiellement soutenir des patients immunodéprimés ou ceux à haut risque d'infection. L'Mpox, une maladie virale infectieuse affectant les humains et les animaux, a enregistré plus de 100 000 cas confirmés et 200 décès dans le monde depuis le début de la surveillance en 2022, selon l'Organisation mondiale de la santé.
TC BioPharm (NASDAQ: TCBP) hat eine Forschungsplanungs-Kooperation mit Dr. Carlos Maluquer de Motes zur Entwicklung einer Behandlung für Affenpocken angekündigt. Dr. Maluquer de Motes ist Dozent und Hauptforscher an der Universität Surrey und hat Expertise in viralen Krankheiten. TC BioPharm glaubt, dass ihre führende Therapie TCB008 eine wichtige Rolle bei der Behandlung von Mpox und anderen infektiösen Krankheiten spielen könnte, indem sie ein verstärktes Niveau von gamma delta T-Zellen bereitstellt, um eine effektivere Immunantwort zu erzeugen.
Das Unternehmen plant auch, die Anwendung von TCB008 in einem prophylaktischen Umfeld für infektiöse Krankheiten zu untersuchen, was potenziell immungeschwächte Patienten oder solche mit hohem Infektionsrisiko unterstützen könnte. Mpox, eine infektiöse Viruskrankheit, die Menschen und Tiere betrifft, hat seit Beginn der Überwachung im Jahr 2022 über 100.000 bestätigte Fälle und 200 Todesfälle weltweit zu verzeichnen, so die Weltgesundheitsorganisation.
- Collaboration with expert Dr. Carlos Maluquer de Motes for Mpox treatment research
- Potential application of lead therapeutic TCB008 for treating Mpox and other infectious diseases
- Exploration of TCB008 for prophylactic use in high-risk patients
- None.
Insights
The collaboration between TC BioPharm and Dr. Carlos Maluquer de Motes for Mpox therapeutic development is an interesting research initiative, but its immediate impact on investors is likely While the company's gamma-delta T cell therapy platform shows potential for viral infections, this is still in the early planning stages.
Key points to consider:
- TC BioPharm's lead therapeutic TCB008 is being explored for both treatment and prophylactic use in viral infections.
- The company aims to address an underserved market, with over 100,000 confirmed Mpox cases globally since 2022.
- However, no specific timelines, financial details, or expected milestones were provided, limiting the ability to assess near-term impact.
Investors should view this as a long-term research endeavor that may diversify TC BioPharm's pipeline but is unlikely to affect financials or stock performance in the short term. The collaboration's true value will depend on future clinical progress and results.
Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of
"We've seen the ramifications of a global pandemic and the havoc it can inflict," said Bryan Kobel, CEO of TC BioPharm. "There is significant data stating that a successful immune response to viral infection is heavily reliant on the presence of gamma delta t-cells, both in the preventative sense and in the successful outcomes of patients with viral infection. We believe that our lead therapeuticTCB008 could play an important role in treating this virus as well as other infectious diseases, providing a bolstered level of gamma delta t-cells to generate a more effective immune response in patients who are facing severe viral infection TCB also intends to explore the use of TCB008 in a prophylactic setting for infectious diseases with the intent to provide TCB008 in a supportive or adjunct use for patients at high risk of infection to various diseases when immune-compromised or suppressed in hospital settings or by age where the immune system and gamma delta t-cell population has weakened. After meeting with a number of experts, our team and I were impressed with Carlos' approach to this potential research plan and his prior stellar work in infectious disease research. We look forward to working with Dr. Maluquer de Motes and playing an important role in addressing this underserved need."
Mpox is an infectious viral disease that can occur in humans and other animals. Symptoms include a rash that forms blisters, fever, and swollen lymph nodes. Since the beginning of Mpox monitoring in 2022, there have been more than 100,000 confirmed cases including over 200 deaths. Cases have been reported by more than 120 countries globally according to the World Health Organization (WHO).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treating acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-enters-research-planning-collaboration-with-dr-carlos-maluquer-de-motes-for-mpox-therapeutic-302282990.html
SOURCE TC BioPharm
FAQ
What is TC BioPharm's new research collaboration for Mpox treatment?
How many confirmed Mpox cases have been reported since 2022?
What are TC BioPharm's plans for TCB008 beyond Mpox treatment?
Who is Dr. Carlos Maluquer de Motes collaborating with TC BioPharm (TCBP)?
